Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose.

Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM.

J Am Soc Nephrol. 2014 Apr;25(4):819-26. doi: 10.1681/ASN.2013060575. Epub 2014 Jan 23.

2.

The ESRD demonstration project: what it accomplished. Fresenius Medical Care North America.

Sauer PF, Farrell RE, Lazarus JM.

Nephrol News Issues. 2011 Jun;25(7):32, 34-5, 37-8. No abstract available.

PMID:
21736133
3.

Abandoning peracetic acid-based dialyzer reuse is associated with improved survival.

Lacson E Jr, Wang W, Mooney A, Ofsthun N, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2011 Feb;6(2):297-302. doi: 10.2215/CJN.03160410. Epub 2010 Oct 14.

4.

Change in vascular access and hospitalization risk in long-term hemodialysis patients.

Lacson E Jr, Wang W, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2010 Nov;5(11):1996-2003. doi: 10.2215/CJN.08961209. Epub 2010 Sep 30.

5.

Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.

Williams ME, Lacson E Jr, Wang W, Lazarus JM, Hakim R.

Clin J Am Soc Nephrol. 2010 Sep;5(9):1595-601. doi: 10.2215/CJN.09301209. Epub 2010 Jul 29.

6.

Digoxin associates with mortality in ESRD.

Chan KE, Lazarus JM, Hakim RM.

J Am Soc Nephrol. 2010 Sep;21(9):1550-9. doi: 10.1681/ASN.2009101047. Epub 2010 Jun 24.

7.

Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.

Chan KE, Thadhani R, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2010 May;5(5):856-66. doi: 10.2215/CJN.07161009. Epub 2010 Mar 25.

8.

The "right" of passage: surviving the first year of dialysis.

Wingard RL, Chan KE, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2009 Dec;4 Suppl 1:S114-20. doi: 10.2215/CJN.04360709.

9.

A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients.

Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2010 Feb;5(2):252-60. doi: 10.2215/CJN.07231009. Epub 2009 Dec 17.

10.

Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program.

Lacson E Jr, Wang W, Lester K, Ofsthun N, Lazarus JM, Hakim RM.

Clin J Am Soc Nephrol. 2010 Feb;5(2):220-6. doi: 10.2215/CJN.06070809. Epub 2009 Dec 3.

11.

Association between achievement of hemodialysis quality-of-care indicators and quality-of-life scores.

Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim R.

Am J Kidney Dis. 2009 Dec;54(6):1098-107. doi: 10.1053/j.ajkd.2009.07.017. Epub 2009 Sep 25.

PMID:
19782455
12.

Change in vascular access and mortality in maintenance hemodialysis patients.

Lacson E Jr, Wang W, Lazarus JM, Hakim RM.

Am J Kidney Dis. 2009 Nov;54(5):912-21. doi: 10.1053/j.ajkd.2009.07.008. Epub 2009 Sep 12.

PMID:
19748717
13.

Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.

Chan KE, Lazarus JM, Thadhani R, Hakim RM.

J Am Soc Nephrol. 2009 Oct;20(10):2223-33. doi: 10.1681/ASN.2009030319. Epub 2009 Aug 27.

14.

Association between repeat hospitalization and early intervention in dialysis patients following hospital discharge.

Chan KE, Lazarus JM, Wingard RL, Hakim RM.

Kidney Int. 2009 Aug;76(3):331-41. doi: 10.1038/ki.2009.199. Epub 2009 Jun 10.

15.

Hemodialysis facility-based quality-of-care indicators and facility-specific patient outcomes.

Lacson E Jr, Wang W, Lazarus JM, Hakim RM.

Am J Kidney Dis. 2009 Sep;54(3):490-7. doi: 10.1053/j.ajkd.2009.01.260. Epub 2009 Apr 29.

PMID:
19406544
16.

Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.

Chan KE, Lazarus JM, Thadhani R, Hakim RM.

J Am Soc Nephrol. 2009 Apr;20(4):872-81. doi: 10.1681/ASN.2008080824. Epub 2009 Mar 18.

17.

Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.

Lacson E Jr, Wang W, Hakim RM, Teng M, Lazarus JM.

Am J Kidney Dis. 2009 Jan;53(1):79-90. doi: 10.1053/j.ajkd.2008.07.031. Epub 2008 Oct 18.

PMID:
18930570
18.

The association of race with erythropoietin dose in patients on long-term hemodialysis.

Lacson E Jr, Rogus J, Teng M, Lazarus JM, Hakim RM.

Am J Kidney Dis. 2008 Dec;52(6):1104-14. doi: 10.1053/j.ajkd.2008.07.026. Epub 2008 Sep 27.

PMID:
18824287
19.

Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA.

Williams ME, Lacson E Jr, Teng M, Hakim RM, Lazarus JM.

Am J Nephrol. 2009;29(1):54-61. doi: 10.1159/000151276. Epub 2008 Aug 8.

PMID:
18689979
20.

Comparison of hemodialysis blood access flow rates using online measurement of conductivity dialysance and ultrasound dilution.

Lacson E Jr, Lazarus JM, Panlilio R, Gotch F.

Am J Kidney Dis. 2008 Jan;51(1):99-106.

PMID:
18155538
21.

The association between blood pressure and mortality in ESRD-not different from the general population?

Lacson E Jr, Lazarus JM.

Semin Dial. 2007 Nov-Dec;20(6):510-7. Review.

PMID:
17991196
22.

Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs.

Lacson E Jr, Ikizler TA, Lazarus JM, Teng M, Hakim RM.

J Ren Nutr. 2007 Nov;17(6):363-71.

PMID:
17971308
23.

Balancing Fistula First with Catheters Last.

Lacson E Jr, Lazarus JM, Himmelfarb J, Ikizler TA, Hakim RM.

Am J Kidney Dis. 2007 Sep;50(3):379-95. Review.

PMID:
17720517
24.

Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.

Lazarus JM, Hakim RM.

Am J Kidney Dis. 2007 Sep;50(3):366-70. No abstract available.

PMID:
17720515
25.

Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients.

Ofsthun NJ, Lazarus JM.

Blood Purif. 2007;25(1):31-5. Epub 2006 Dec 14.

PMID:
17170534
26.

Translating epoetin research into practice: the role of government and the use of scientific evidence.

Lazarus JM, Hakim RM.

Nephrol News Issues. 2006 Dec;20(13):12, 22. No abstract available.

PMID:
17168053
27.

The epidemiology of systolic blood pressure and death risk in hemodialysis patients.

Li Z, Lacson E Jr, Lowrie EG, Ofsthun NJ, Kuhlmann MK, Lazarus JM, Levin NW.

Am J Kidney Dis. 2006 Oct;48(4):606-15.

PMID:
16997057
28.

Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival.

Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM.

Kidney Int. 2006 Oct;70(8):1503-9. Epub 2006 Aug 30.

29.

Evaluating a new method to judge dialysis treatment using online measurements of ionic clearance.

Lowrie EG, Li Z, Ofsthun NJ, Lazarus JM.

Kidney Int. 2006 Jul;70(1):211-7. Epub 2006 May 24.

30.

Dialyzer best practice: single use or reuse?

Lacson E Jr, Lazarus JM.

Semin Dial. 2006 Mar-Apr;19(2):120-8. Review.

PMID:
16551289
31.

Dedicated outpatient vascular access center decreases hospitalization and missed outpatient dialysis treatments.

Mishler R, Sands JJ, Ofsthun NJ, Teng M, Schon D, Lazarus JM.

Kidney Int. 2006 Jan;69(2):393-8.

32.

Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients.

Chertow GM, Goldstein-Fuchs DJ, Lazarus JM, Kaysen GA.

Kidney Int. 2005 Dec;68(6):2794-800.

33.

The emperor has no clothes (but has a catheter): a perspective on the state of chronic kidney disease care.

Lazarus JM, Hakim RM, Maddux FW, Amedia CA Jr.

Nephrol News Issues. 2005 Nov;19(12):45-6, 48.

PMID:
16315544
34.

Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease.

Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM.

Hemodial Int. 2005 Oct;9(4):367-75.

PMID:
16219057
35.

Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.

Collins AJ, Brenner RM, Ofman JJ, Chi EM, Stuccio-White N, Krishnan M, Solid C, Ofsthun NJ, Lazarus JM.

Am J Kidney Dis. 2005 Sep;46(3):481-8.

PMID:
16129210
36.

The online measurement of hemodialysis dose (Kt): clinical outcome as a function of body surface area.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Kidney Int. 2005 Sep;68(3):1344-54.

37.

Activated injectable vitamin D and hemodialysis survival: a historical cohort study.

Teng M, Wolf M, Ofsthun MN, Lazarus JM, HernĂ¡n MA, Camargo CA Jr, Thadhani R.

J Am Soc Nephrol. 2005 Apr;16(4):1115-25. Epub 2005 Feb 23.

38.

Measurement of dialyzer clearance, dialysis time, and body size: death risk relationships among patients.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Kidney Int. 2004 Nov;66(5):2077-84.

39.

Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis.

Pillon L, Piccoli A, Lowrie EG, Lazarus JM, Chertow GM.

Kidney Int. 2004 Sep;66(3):1266-71.

40.

Reprocessing dialysers for multiple uses: recent analysis of death risks for patients.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Nephrol Dial Transplant. 2004 Nov;19(11):2823-30. Epub 2004 Aug 17.

PMID:
15316099
41.

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM.

J Am Soc Nephrol. 2004 Aug;15(8):2208-18.

42.

Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients.

Szczech LA, Reddan DN, Klassen PS, Coladonato J, Chua B, Lowrie EG, Lazarus JM, Owen WF Jr.

Nephrol Dial Transplant. 2003 Aug;18(8):1585-91.

PMID:
12897099
43.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.

N Engl J Med. 2003 Jul 31;349(5):446-56.

44.

Quality of care in profit vs not-for-profit dialysis centers.

Bosch J, Hakim RM, Lazarus JM, McAllister CJ.

JAMA. 2003 Jun 18;289(23):3087-8; author reply 3089-90. No abstract available.

PMID:
12813111
45.

The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.

Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM.

Kidney Int. 2003 May;63(5):1908-14.

46.

The association between mental health, physical function, and hemodialysis mortality.

Knight EL, Ofsthun N, Teng M, Lazarus JM, Curhan GC.

Kidney Int. 2003 May;63(5):1843-51.

47.

Toward a continuous quality improvement paradigm for hemodialysis providers with preliminary suggestions for clinical practice monitoring and measurement.

Lowrie EG, Teng M, Lew NL, Lacson EJ, Lazarus JM, Owen WF.

Hemodial Int. 2003 Jan 1;7(1):28-51. doi: 10.1046/j.1492-7535.2003.00003.x.

PMID:
19379340
48.

Effect of variability in anemia management on hemoglobin outcomes in ESRD.

Lacson E Jr, Ofsthun N, Lazarus JM.

Am J Kidney Dis. 2003 Jan;41(1):111-24.

PMID:
12500228
49.

Body size, dialysis dose and death risk relationships among hemodialysis patients.

Lowrie EG, Li Z, Ofsthun N, Lazarus JM.

Kidney Int. 2002 Nov;62(5):1891-7.

50.

Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis.

Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr.

JAMA. 2002 Mar 27;287(12):1548-55.

PMID:
11911757

Supplemental Content

Loading ...
Support Center